At the national level, I have been one of the leaders of the GETAID group, initiating and participating to many clinical trials that have helped to improve therapeutic strategies in IBD especially regarding the use of immunomodulators and biologics. cerevisiae (mannan) antibodies) which is still the most sensitive and specific serologic marker for CD and elucidation of the potential role of Candida albicans in CD and the identification of a new pathovar of Escherichia coli (AIEC for adhesive invasive E.coli) associated with ileal CD. The most remarkable are the initiation in 1994 of collection and sampling of IBD families that eventually led to the identificationof NOD2 as a susceptibility gene for CD, the development in the 90’s of the ASCA test (anti- S.
![frederic longuepee bio frederic longuepee bio](https://s1.static-footeo.com/uploads/fc-girondins-de-bordeaux/executives/frederic-longuepee__px454r.png)
Thanks to the development of multiple local, national and international collaborations we have been able to make some important contributions to the pathophysiology of IBD. Our research center was composed of 3 complementary groups: (1) a medical and surgical department which has performed many multicenter studies at the national (GETAID group) and international level (2) an epidemiological group based upon the IBD North-Western Registry (EPIMAD) (3) a physiopathological group devoted to the study of immunological mechanisms and the development of new therapeutic targets in regulation of digestive inflammation. Over the past 20 years I have set up in Lille (France) together with my colleagues a successful comprehensive research and health care network fully dedicated to Inflammatory Bowel Diseases (Crohn’s disease and ulcerative colitis ).